Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin“s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.

Borchmann, P; Haverkamp, H; Diehl, V; Cerny, T; Markova, J; Ho, AD; Eich, HT; Mueller-Hermelink, HK; Kanz, L; Greil, R; Rank, A; Paulus, U; Smardova, L; Huber, C; Dörken, B; Nerl, C; Krause, SW; Mueller, RP; Fuchs, M; Engert, A; J Clin Oncol. 2011; 29(32): 423-442.

ASH Report. Novel agents in diffuse large B-cell lymphoma: A short update including ASH 2010.

Melchardt, T; Hofbauer, SW; Greil, R; Hopfinger, G memo – Magazine of European Medical Oncology. 2011; 4: 120-123.

Treatment of invasive aspergillosis in cancer patients.

Auberger, J; Russ, G; Greil, R; Egle, A; memo – Magazine of European Medical Oncology. 2011; 4 (4): 266-272.

Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.

Scherzer, TM; Stättermayer, AF; Strasser, M; Laferl, H; Maieron, A; Stauber, R; Datz, C; Dulic-Lakovic, E; Steindl-Munda, P; Hofer, H; Ferenci, P; HEPATOLOGY. 2011; 54(5): 1518-1526.

Infusion reactions to the chimeric EGFR inhibitor cetuximab-change to the fully human anti-EGFR monoclonal antibody panitumumab is safe

Resch, G; Schaberl-Moser, R; Kier, P; Kopetzky, G; Scheithauer, W; Sliwa, T; Greil, R; Nosslinger, T; Mayrbaurl, B; Thaler, J ANN ONCOL. 2011; 22(2): 486-U251.

Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.

Ofner, D; Devries, AF; Schaberl-Moser, R; Greil, R; Rabl, H; Tschmelitsch, J; Zitt, M; Kapp, KS; Fastner, G; Keil, F; Eisterer, W; Jäger, R; Offner, F; Gnant, M; Thaler, J; Strahlenther Onkol. 2011; 187(2): 100-107.

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

Eichhorst, BF; Fischer, K; Fink, AM; Elter, T; Wendtner, CM; Goede, V; Bergmann, M; Stilgenbauer, S; Hopfinger, G; Ritgen, M; Bahlo, J; Busch, R; Hallek, M BLOOD. 2011; 117(6): 1817-1821.

Assessing protein immunogenicity with a dendritic cell line-derived endolysosomal degradome.

Egger, M; Jurets, A; Wallner, M; Briza, P; Ruzek, S; Hainzl, S; Pichler, U; Kitzmuller, C; Bohle, B; Huber, CG; Ferreira, F PLoS One. 2011; 6(2):e17278

Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.

Hofbauer, JP; Heyder, C; Denk, U; Kocher, T; Holler, C; Trapin, D; Asslaber, D; Tinhofer, I; Greil, R; Egle, A; Leukemia. 2011; 25(9): 1452-1458.

Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma.

Gökbuget, N; Hartog, CM; Bassan, R; Derigs, HG; Dombret, H; Greil, R; Hernández-Rivas, JM; Huguet, F; Intermesoli, T; Jourdan, E; Junghanss, C; Leimer, L; Moreno, MJ; Reichle, A; Ribera, J; Schmid, M; Serve, H; Stelljes, M; Stuhlmann, R; Hoelzer, D; Haematologica. 2011; 96(2): 238-244.